Why the study?
It was unclear whether the bleeding reduction observed with rivaroxaban regimens was consistent across a range of INR stability among AF patients receiving VKA-triple therapy after PCI.
Do rivaroxaban-based strategies reduce clinically significant bleeding compared to warfarin plus dual antiplatelet therapy regardless of INR stability in atrial fibrillation patients undergoing percutaneous coronary intervention?
RCT (n=2,124)
Open-label
Randomized
Yes
Do rivaroxaban-based strategies reduce clinically significant bleeding compared to warfarin plus dual antiplatelet therapy regardless of INR stability in atrial fibrillation patients undergoing percutaneous coronary intervention?
Rivaroxaban-based antithrombotic strategies reduce bleeding compared to warfarin plus DAPT in AF patients undergoing PCI, even when warfarin is well-managed with high time in therapeutic range.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kernéis et al. (2019) conducted an RCT in Atrial fibrillation undergoing percutaneous coronary intervention (n=2,124). Rivaroxaban vs. Warfarin plus dual antiplatelet therapy was evaluated on Clinically significant bleeding (HR ranges 0.42-0.76, p=<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: